PDCD1 and melanoma: CT26 was highly responsive to CTLA4 checkpoint inhibitors, but not to PD-1 inhibitors, while other models including the B16F10 melanoma model did not respond significantly to either of the checkpoint inhibitors (Additional file 2: Figure S5).